721 AT1412, a patient-derived CD9 antibody in preclinical development promoting tumor immune infiltration and inducing tumor rejection

721 AT1412, a patient-derived CD9 antibody in preclinical development promoting tumor immune infiltration and inducing tumor rejection

Bibliographic Details
Main Authors: Els Verdegaal, Hergen Spits, Remko Schotte, Martijn Kedde, Gemma Moiset, Hans Van Eenennaam, Pauline van Helden, Sjoerd van der Burg, Julien Villaudy, Wouter Pos, Daniel Go, Christien Fatmawati, Etsuko Yasuda, Madalina Cercel, Esmay Frankin, Susan van Hal
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items